An alliterative acquisition for Alexion

Alexion Pharmaceuticals is boosting its arsenal of experimental drugs that treat rare immune disorders: The company just acquired Achillion Pharmaceuticals for $930 million.

Alexion is largely reliant on two injectable drugs — Soliris and Ultomiris — and has been seeking to expand its pipeline. Even before news of the acquisition, Achillion had been testing its oral drug, danicopan, in conjunction with Soliris in patients with paroxysmal nocturnal hemoglobinuria. Achillion has also been testing danicopan to treat an ultra-rare kidney disease called C3 glomerulopathy.

Read more.